UNC-CH treats patient with novel genome-editing therapy – WRAL Tech Wire
WRAL Tech Wire |
UNC-CH treats patient with novel genome-editing therapy
WRAL Tech Wire CHAPEL HILL – A man suffering from a rare genetic disease has been treated with a novel genome-editing therapy at the University of North Carolina’s Clinical and Translational Research Center. The therapy, called SB-913, is based on a proprietary … |
Equities.com |
Why IMV Wants You to Rethink What You Know About Immunotherapy — Q&A with CEO Frederic Ors
Equities.com Unlike traditional oncology methods, immunotherapies aim to trigger native responses of the body’s own immune system to attack cancer cells. But there’s a critical flaw in this approach, and it’s one that could significantly limit the potential for … |
Science Daily |
Let them eat xylose: Yeast engineered to grow efficiently on novel nutrients
Science Daily In synthetic biology, organisms such as bacteria or yeast may be transformed into “mini-factories” when fed nutrients to produce a wide range of products, from pharmaceuticals to industrial chemicals and biofuels. However, a central challenge has been … Yeast Feast on Xylose and Grow Quickly If Regulon Is Table d’HôteGenetic Engineering & Biotechnology News |
The Conversation UK |
Gene therapies are proving their worth, but with million dollar price tags, it’s not clear who should pay for them
The Conversation UK That’s because gene therapies became a clinical reality in 2017. Yet many people with rare diseases that could be treated in this way may never benefit from these therapies because they are too expensive for drug companies to develop, or too costly for … |